Shares of Cardica Inc. (NASDAQ:DXTR) have earned a consensus broker rating score of 2.00 (Buy) from the two analysts that cover the company, Zacks Investment Research reports. One analyst has rated the stock with a hold rating and one has assigned a strong buy rating to the company.

Brokerages have set a twelve-month consensus target price of $8.50 for the company and are expecting that the company will post ($0.48) EPS for the current quarter, according to Zacks. Zacks has also given Cardica an industry rank of 91 out of 265 based on the ratings given to related companies.

Separately, Zacks Investment Research downgraded Cardica from a “buy” rating to a “hold” rating in a report on Monday, September 5th.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/zacks-cardica-inc-nasdaqdxtr-given-average-recommendation-of-buy-by-analysts.html

Shares of Cardica (NASDAQ:DXTR) traded up 0.5179% during midday trading on Wednesday, hitting $1.9601. The company had a trading volume of 7,644 shares. The stock’s market capitalization is $17.44 million. Cardica has a one year low of $1.10 and a one year high of $4.30. The stock’s 50-day moving average price is $2.15 and its 200-day moving average price is $2.67.

Cardica (NASDAQ:DXTR) last issued its earnings results on Tuesday, August 9th. The company reported ($0.48) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.47) by $0.01. Cardica had a negative net margin of 394.39% and a negative return on equity of 688.02%. Analysts predict that Cardica will post ($1.53) EPS for the current year.

About Cardica

Dextera Surgical Inc, formerly Cardica, Inc, is focused on the commercialization and development of microcutter product line intended for use by surgeons. The Company is engaged in commercializing and developing MicroCutter XCHANGE 30 based on its staple-on-a-strip technology for use by thoracic, pediatric, bariatric, colorectal and general surgeons.

5 Day Chart for NASDAQ:DXTR

Get a free copy of the Zacks research report on Cardica (DXTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cardica Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardica Inc. and related companies with MarketBeat.com's FREE daily email newsletter.